

Extremely low penetrance of deafness associated with the mitochondrial 12S rRNA mutation in 16 Chinese families: Implication for early detection and prevention of deafness

Pu Dai ^{a,1}, Xin Liu ^{a,1}, Dongyi Han ^{a,*}, Yaping Qian ^b, Deliang Huang ^a, Huijun Yuan ^a, Weiming Li ^a, Fei Yu ^a, Ruining Zhang ^c, Hongyan Lin ^d, Yong He ^e, Youjun Yu ^f, Quanzhu Sun ^g, Huaiyi Qin ^h, Ronghua Li ^b, Xin Zhang ^a, Dongyang Kang ^a, Juyang Cao ^a, Wie-Yen Young ^{a,*}, Min-Xin Guan ^{b,1,*}

^a Department of Otolaryngology, Chinese PLA General Hospital, Beijing, China

^b Division and Program in Human Genetics and Center for Hearing and Deafness Research, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

^c Department of Otolaryngology, Yuncheng Central Hospital, Yuncheng, Shanxi 044000, China

^d Department of Otolaryngology, Anyang Stomatology Hospital, Anyang, Henan 455000, China

^e Department of Otolaryngology, Fuzhou Second Hospital, Fozhou, Fujian 528000, China

^f Department of Otolaryngology, Foshan First People's Hospital, Foshan, Guangdong 528000, China

^g Department of Otolaryngology, Datong Third People's Hospital, Datong, Shanxi 037008, China

^h Blind, Deaf and Dumb School, Liuzhou, Guangxi 545005, China

ⁱ Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA

Received 18 November 2005

Available online 9 December 2005

Abstract

Mutations in mitochondrial DNA (mtDNA) have been found to be associated with sensorineural hearing loss. We report here the clinical, genetic, and molecular characterization of 16 Chinese pedigrees (a total of 246 matrilineal relatives) with aminoglycoside-induced impairment. Clinical evaluation revealed the variable phenotype of hearing impairment including audiometric configuration in these subjects, although these subjects share some common features: being bilateral and sensorineural hearing impairment. Strikingly, these Chinese pedigrees exhibited extremely low penetrance of hearing loss, ranging from 4% to 18%, with an average of 8%. In particular, nineteen of 246 matrilineal relatives in these pedigrees had aminoglycoside-induced hearing loss. Mutational analysis of the mtDNA in these pedigrees showed the presence of homoplasmic 12S rRNA A1555G mutation, which has been associated with hearing impairment in many families worldwide. The extremely low penetrance of hearing loss in these Chinese families carrying the A1555G mutation strongly supports the notion that the A1555G mutation itself is not sufficient to produce the clinical phenotype. Children carrying the A1555G mutation are susceptible to the exposure of aminoglycosides, thereby inducing or worsening hearing impairment, as in the case of these Chinese families. Using those genetic and molecular approaches, we are able to diagnose whether children carry the ototoxic mtDNA mutation. Therefore, these data have been providing valuable information and technology to predict which individuals are at risk for ototoxicity, to improve the safety of aminoglycoside therapy, and eventually to decrease the incidence of deafness.

© 2005 Elsevier Inc. All rights reserved.

Keywords: Deafness; Mitochondrial 12S rRNA mutation; Aminoglycoside; Penetrance; Ototoxicity; Maternally transmitted; Prevention; Detection; Chinese

* Corresponding authors. Fax: +1 513 636 3486 (M.-X. Guan).

E-mail addresses: hdy301@263.net (D. Han), ywy301@163.net (W.-Y. Young), min-xin.guan@cchmc.org (M.-X. Guan).

¹ These authors have equally contributed to this work.

The use of aminoglycoside antibiotics, such as gentamicin, streptomycin, kanamycin, and tobramycin, can lead to irreversible ototoxicity [1,2]. In particular, susceptibility to aminoglycoside-induced hearing loss is maternally inherited in humans in a significant proportion of cases, particularly in the Chinese populations [3–5]. Hu et al. [3] described 36 Chinese families with maternally transmitted predisposition to aminoglycoside ototoxicity, while Higashi reported that 26 of 28 families with streptomycin-induced deafness had maternally inherited transmission [4]. These drugs are known to exert their antibacterial effects by directly binding to 16S ribosomal RNA (rRNA) in the 30S subunit of the bacterial ribosome, causing mistranslation or premature termination of protein synthesis [6,7]. Mitochondrial ribosomes share more similarities to bacterial ribosomes than do cytosolic ribosomes [8,9]. Therefore, it is proposed that the ototoxic site of aminoglycosides is the mitochondrial ribosome. Thus, mutation(s) in mitochondrial DNA (mtDNA), particularly in 12S rRNA gene, could be the molecular basis for this susceptibility [8,9].

Sequence analyses of the mitochondrial genome in patients with aminoglycoside ototoxicity have led to the identification of several ototoxic mtDNA mutations in the 12S rRNA gene [8,9]. Of those, the C1494T mutation in the highly conserved A-site of 12S rRNA has been associated with both aminoglycoside-induced and nonsyndromic hearing loss in a large Chinese family [10,11]. By contrast, the homoplasmic A1555G mutation in the highly conserved A-site of the 12S rRNA has been associated with both aminoglycoside-induced and nonsyndromic hearing loss in many families worldwide [12–21]. In particular, matrilineal relatives within intra-families or with families carrying the A1555G mutation exhibited the variable expressivity and penetrance of hearing impairment [12,13,15]. Incomplete and variable penetrance of hearing loss as well as a mild biochemical defect associated with this mutation indicated that the A1555G mutation itself is not sufficient to produce the clinical phenotype [12,13,15,19,22,23]. Therefore, aminoglycosides, nuclear modifier genes, and/or other mtDNA mutations/polymorphisms modulate the phenotypic variability and penetrance of deafness associated with the A1555G mutation [22–24].

To understand the pathogenesis of maternally inherited aminoglycoside-induced and nonsyndromic hearing loss, a systematic and extended mutational analysis of mitochondrial 12S rRNA has been initiated at Department of Otolaryngology of the Chinese PLA General Hospital [19–21]. In the present study, we report the clinical, molecular, and genetic characterization of 16 Chinese pedigrees with aminoglycoside-induced hearing loss. Clinical and genetic evaluation revealed extremely low penetrance of hearing loss in these Chinese families. Mutational analysis of 12S rRNA has led to the identification of the A1555G mutation in those families. Those results support the idea that the A1555G mutation is not sufficient to produce a clinical phenotype and aminoglycosides are the major modifier factor for the development of deafness in these Chinese fam-

ilies. Thus, these observations provide a direct evidence for the early detection and prevention of deafness at the high risk populations carrying this mtDNA mutations.

Subjects and methods

Subjects and audiological examinations. As the part of the genetic screening program for hearing impairment, 16 Chinese families were ascertained through the Otolaryngology Clinic at Chinese PLA General Hospital. A comprehensive history and physical examination performed to identify any syndromic findings, the history of the use of aminoglycosides, and genetic factors related to hearing impairment in members of these pedigrees. An age-appropriate audiological examination was performed and this examination included pure-tone audiometry (PTA) and/or auditory brainstem response (ABR), immittance testing, and Distortion product otoacoustic emissions (DPOAE). The PTA was calculated from the sum of the audiometric thresholds at 500, 1000 and 2000, 4000, and 8000 Hz. The severity of hearing impairment was classified into five grades: normal <26 dB; mild = 26–40 dB; moderate = 41–70 dB; severe = 71–90 dB; and profound >90 dB. Informed consent was obtained from participants prior to their participation in the study, in accordance with the Cincinnati Children's Hospital Medical Center Institutional Review Board and Ethic Committee of Chinese PLA General Hospital.

Mutational analysis of mitochondrial genome. Genomic DNA was isolated from whole blood of participants using Puregene DNA Isolation Kits (Gentra Systems). Subject's DNA fragments spanning the entire mitochondrial 12S rRNA gene were amplified by PCR using oligodeoxynucleotides corresponding to positions 618–635 and 1988–2007 [25]. For the detection of the A1555G mutation, the amplified segments were first digested with a restriction enzyme *BsmAI* [13]. Equal amounts of various digested samples were then analyzed by electrophoresis through 1.5% agarose gel. The proportions of digested and undigested PCR product were determined by laser densitometry after ethidium bromide staining to determine if the A1555G mutation is in homoplasmy in these subjects. To confirm the presence of the A1555G mutation in each proband, the amplified segments were purified and subsequently analyzed by direct sequencing in an ABI 3700 automated DNA sequencer using the Big Dye Terminator Cycle sequencing reaction kit. The resultant sequence data were compared with the updated consensus Cambridge sequence (GenBank Accession No. NC_001807) [26].

Results and discussion

To further elucidate the molecular basis of aminoglycoside ototoxicity, we have performed a mutational analysis of the mitochondrial 12S rRNA gene in a cohort of Chinese subjects, who were diagnosed as aminoglycoside ototoxicity by the Otolaryngology Clinic at the Chinese PLA General Hospital. First, DNA fragments spanning mitochondrial 12S rRNA were PCR amplified from each affected subject. Each fragment was digested by restriction enzyme *BsmAI* and subsequent electrophoresis analysis. Of those subjects, as shown in Fig. 1, 16 subjects with aminoglycoside ototoxicity carry the homoplasmic A1555G mutation in the 12S rRNA gene. To confirm the presence of the A1555G mutation in those subjects, these PCR-amplified segments were then purified and subsequently analyzed by DNA sequencing. Indeed, the sequence analysis confirmed the presence of the A1555G mutation in these subjects.

In fact, all those 16 subjects, as shown in Table 1, had been administered aminoglycosides (3–5 mg/kg/dose every




Fig. 1. Qualification of the A1555G mutation of 16 Chinese subjects with aminoglycoside-induced hearing loss. PCR products around A1555G region of mitochondrial genome were digested with *Bsm*AI and analyzed by electrophoresis in a 1.5% agarose gel stained with ethidium bromide. A2 is a Chinese control subject.

Table 1
Summary of clinical data for hearing-impaired subjects in 16 Chinese pedigrees carrying the A1555G mutation

Subject	Gender	Age at test (years)	Age at onset (years)	Use of aminoglycosides	PTA (dB) right ear	PTA (dB) left ear	Audiometric configuration	Level of hearing impairment	Penetrance of pedigrees ^a (%)
BJ201-III-4	M	17	6	Gentamicin	95	95	Slope	Profound	18.18
BJ202-III-3	M	22	2	Streptomycin/kanamycin	95	95	Flat	Profound	15.38
BJ203-III-6	F	19	1	Gentamicin	100	100	Flat	Profound	8.33
BJ204-III-3	M	17	3	Gentamicin/streptomycin	95	95	Flat	Profound	11.11
BJ205-III-5	M	17	1.5	Streptomycin	90	86	Ridge	Severe	11.76
BJ206-III-17	M	15	1.5	Gentamicin	90	100	Ridge	Profound	4.54
BJ207-III-10	F	16	3	Gentamicin	93	93	Slope	Profound	8.33
BJ208-III-14	M	8	1	Gentamicin	100	100	Flat	Profound	4.76
BJ209-IV-4	M	12	1	Gentamicin/kanamycin	85	85	Slope	Severe	10.00
BJ210-III-5	M	18	1	Gentamicin/streptomycin	75	78	Slope	Severe	4.17
BJ211-III-12	M	19	2	Streptomycin	85	89	Ridge	Severe	8.33
BJ212-III-3	M	13	1.5	Gentamicin	85	85	Slope	Severe	9.09
BJ213-III-1	M	12	1.5	Gentamicin	85	90	Slope	Severe	7.69
BJ214-III-9	M	18	1	Gentamicin/kanamycin/streptomycin	100	100	Flat	Profound	5
BJ215-IV-10	F	15	9	Gentamicin/streptomycin	100	100	Flat	Profound	4
BJ216-III-11	M	24	1	Gentamicin/streptomycin	92	91	Slope	Profound	7.14

^a Penetrance = affected matrilineal relatives/total matrilineal relatives.

8 h for gentamicin or 15–25 mg/kg/dose every 12 h for streptomycin or 7.5 mg/kg/every 18 h for kanamycin) for various illnesses at the ages of 1 year to 9 years. They began suffering bilateral hearing impairment within three months after drug administration. As illustrated in Fig. 2, audiological evaluation showed that all those subjects showed the loss of high frequencies and their hearing impairment was symmetric. Those subjects, as shown in Table 1, exhibited a variable severity of hearing impairment: 10 subjects suffered from profound hearing impairment and 6 individuals had severe hearing impairment. Those subjects also displayed variable patterns of audiometric configuration: six subjects had the flat pattern, seven subjects showed the sloping pattern, and three individuals exhibited the ridge pattern.

A comprehensive history and physical examination as well as audiological examination were performed to identify any syndromic findings, the history of the use of aminoglycosides, and genetic factors related to the hearing

impairment in all available members of 16 Chinese families carrying the A1555G mutation. In fact, comprehensive family medical histories of those probands and other members of these Chinese families showed no other clinical abnormalities, including diabetes, muscular diseases, visual dysfunction, and neurological disorders. Strikingly, these 16 Chinese families exhibited extremely low penetrance of hearing loss, ranging from 4% to 18%, with an average of 8.6%. In particular, among 13 Chinese families, as shown in Fig. 3, only probands exhibited aminoglycoside-induced hearing loss, while none of other matrilineal relatives including the proband's mother in those families had hearing deficit. In pedigree BJ201, BJ202, and BJ205, only proband and one matrilineal relative in each pedigree suffered from hearing impairment. In fact, all those hearing-impaired matrilineal relatives had a history of exposure to aminoglycosides. By contrast, many other pedigrees carrying the A1555G mutation revealed much higher penetrance of hearing loss than those Chinese pedigrees. For example,




Fig. 2. Air conduction audiogram of 16 affected subjects with the A1555G mutation. Symbols: X, left; O, right ear.

the average penetrance (including aminoglycoside-induced deafness) of three Mongolian pedigrees carrying the A1555G mutation is ~62.5% [16], while ~59% and 67% of matrilineal relatives from BJ110 and BJ105 families, respectively [20,21]. The extremely low penetrance of hearing loss in these Chinese families carrying the A1555G mutation strongly supports the notion that the A1555G mutation itself is not sufficient to produce the clinical phenotype. This is consistent with our previous biochemical data that the A1555G mutation conferred a mild mitochondrial dysfunction [22,23]. Therefore, other modifier factors including the aminoglycosides are necessary for the phenotypic manifestation of the A1555G mutation.

Indeed, the A1555G or C1494T mutation is located in the decoding region of the small ribosomal subunit, which is important for the action of aminoglycosides [27–29]. In

fact, the new U-A or G-C pair in 12S rRNA created by the C1494T or A1555G transition facilitates the binding of aminoglycosides [12,30]. Our previous biochemical data indicated that the A1555G or C1494T mutation led to the sensitivity to aminoglycosides [10,11,22,24]. Thus, children carrying these ototoxic mtDNA mutations are susceptible to the exposure of aminoglycosides, thereby inducing or worsening hearing impairment, as in the case of these Chinese families. These results have significant clinical impact. Using those genetic and molecular approaches, we are able to diagnose whether children carry those ototoxic mtDNA mutations. Therefore, these data have been providing valuable information and technology to predict which individuals are at risk for ototoxicity, to improve the safety of aminoglycoside therapy, and eventually to decrease the incidence of deafness.




Fig. 3. Sixteen Chinese pedigrees with aminoglycoside-induced hearing impairment. Hearing-impaired individuals are indicated by filled symbols. Arrow denotes probands.

Acknowledgments

This work was supported by the National Institutes of Health Grants RO1DC04958 from the National Institute

on Deafness and Other Communication Disorders and ROINS44015 from the National Institute of Neurological Disorders and Stroke to M.X.G. and the Chinese National Nature Science Foundation research Grant 30572015 to P.D.

References

- [1] O. Lortholary, M. Tod, Y. Cohen, O. Petitjean, Aminoglycosides, *Med. Clin. North Am.* 79 (1995) 761–798.
- [2] M.A. Sande, G.L. Mandell, Antimicrobial agents, in: A.G. Gilman, T.W. Rall, A.S. Nies, R. Taylor (Eds.), *Goodman and Gilman's The Pharmacological Basis of Therapeutics*, eighth ed., Pergamon Press, Elmsford, NY, 1990, pp. 1098–1116.
- [3] D.N. Hu, W.Q. Qui, B.T. Wu, L.Z. Fang, Y.P. Gu, Q.H. Zhang, J.H. Yan, Y.Q. Ding, H. Wong, Genetic aspects of antibiotic induced deafness: mitochondrial inheritance, *J. Med. Genet.* 28 (1991) 79–83.
- [4] K. Higashi, Unique inheritance of streptomycin-induced deafness, *Clin. Genet.* 35 (1989) 433–436.
- [5] Z. Li, R. Li, J. Chen, Z. Liao, Y. Zhu, Y. Qian, S. Xiong, S. Heman-Ackah, J. Wu, D.I. Choo, M.-X. Guan, Mutational analysis of the mitochondrial 12S rRNA gene in Chinese pediatric subjects with aminoglycoside induced and non-syndromic hearing loss, *Hum. Genet.* 117 (2005) 9–15.
- [6] H.F. Chamber, M.A. Sande, The aminoglycosides, in: J.G. Hardman, L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Gilman (Eds.), *The Pharmacological Basis of Therapeutic*, Ninth Ed., McGraw-Hill, New York, 1996, pp. 1103–1221.
- [7] J. Davis, B.D. Davis, Misreading of ribonucleic acid code words induced by aminoglycoside antibiotics, *J. Biol. Chem.* 243 (1968) 3312–3316.
- [8] N. Fischel-Ghodsian, Genetic factors in aminoglycoside toxicity, *Pharmacogenomics* 6 (2005) 27–36.
- [9] M.X. Guan, Molecular pathogenetic mechanism of maternally inherited deafness, *Ann. NY Acad. Sci.* 1011 (2004) 259–271.
- [10] H. Zhao, R. Li, Q. Wang, Q. Yan, J.H. Deng, D. Han, Y. Bai, W.Y. Young, M.X. Guan, Maternally inherited aminoglycoside-induced and nonsyndromic deafness is associated with the novel C1494T mutation in the mitochondrial 12S rRNA gene in a large Chinese family, *Am. J. Hum. Genet.* 74 (2004) 139–152.
- [11] H. Zhao, W.Y. Young, Q. Yan, R. Li, J. Cao, Q. Wang, X. Li, J.L. Peters, D. Han, M.X. Guan, Functional characterization of the mitochondrial 12S rRNA C1494T mutation associated with aminoglycoside-induced and nonsyndromic hearing loss, *Nucleic Acid Res.* 33 (2005) 1132–1139.
- [12] T.R. Prezant, J.V. Agopian, M.C. Bohlman, X. Bu, S. Oztas, W.Q. Qiu, K.S. Arnos, G.A. Cortopassi, L. Jaber, J.I. Rotter, M. Shohat, N. Fischel-Ghodsian, Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness, *Nat. Genet.* 4 (1993) 289–294.
- [13] R. Li, G. Xing, M. Yan, X. Cao, X.Z. Liu, X. Bu, M.X. Guan, Cosegregation of C-insertion at position 961 with A1555G mutation of mitochondrial 12S rRNA gene in a large Chinese family with maternally inherited hearing loss, *Am. J. Med. Genet.* 124A (2004) 113–117.
- [14] G. Matthijs, S. Claes, B. Longo-Bbenza, J.-J. Cassiman, Non-syndromic deafness associated with a mutation and a polymorphism in the mitochondrial 12S ribosomal RNA gene in a large Zairean pedigree, *Eur. J. Hum. Genet.* 4 (1996) 46–51.
- [15] X. Estivill, N. Govea, A. Barceló, E. Perelló, C. Badenas, E. Romero, L. Moral, R. Scozzari, L. D'Urbano, M. Zeviani, A. Torroni, Familial progressive sensorineural deafness is mainly due to the mtDNA A1555G mutation and is enhanced by treatment with aminoglycosides, *Am. J. Hum. Genet.* 62 (1998) 27–35.
- [16] A. Pandya, X. Xia, J. Radnaabazar, J. Batsuuri, B. Dangaansuren, N. Fischel-Ghodsian, W.E. Nance, Mutation in the mitochondrial 12S ribosomal-RNA gene in two families from Mongolia with matrilineal aminoglycoside ototoxicity, *J. Med. Genet.* 34 (1997) 169–172.
- [17] N. Fischel-Ghodsian, T.R. Prezant, X. Bu, S. Oztas, Mitochondrial ribosomal RNA gene mutation in a patient with sporadic aminoglycoside ototoxicity, *Am. J. Otolaryng.* 4 (1993) 399–403.
- [18] S.I. Usami, S. Abe, M. Kasai, H. Shinkawa, B. Moeller, J.B. Kenyon, W.J. Kimberling, Genetic and clinical features of sensorineural hearing loss associated with the 1555 mitochondrial mutation, *Laryngoscope* 107 (1997) 483–490.
- [19] W.Y. Young, L. Zhao, R. Li, Q. Wang, Y. Qian, N. Li, J.H. Greinwald, M.X. Guan, Extremely low penetrance of hearing loss in four Chinese families with the mitochondrial 12S rRNA A1555G mutation, *Biochem. Biophys. Res. Commun.* 328 (2005) 1244–1251.
- [20] H. Yuan, Y. Qian, Y. Xu, J. Cao, L. Bai, W. Shen, F. Ji, X. Zhang, D. Kang, J.Q. Mo, J.H. Greinwald, D. Han, S. Zhai, W.Y. Young, M.X. Guan, Cosegregation of the G7444A mutation in the mitochondrial COI/tRNA^{Ser(UCN)} genes with the 12S rRNA A1555G mutation in a Chinese family with aminoglycoside-induced and non-syndromic hearing loss, *Am. J. Med. Genet.* 138A (2005) 133–140.
- [21] L. Zhao, Q. Wang, Y. Qian, R. Li, J. Cao, L.C. Hart, S. Zhai, D. Han, W.Y. Young, M.X. Guan, Clinical evaluation and mitochondrial genome sequence analysis of two Chinese families with aminoglycoside-induced and nonsyndromic hearing loss, *Biochem. Biophys. Res. Commun.* 336 (2005) 967–973.
- [22] M.X. Guan, N. Fischel-Ghodsian, G. Attardi, Biochemical evidence for nuclear gene involvement in phenotype of non-syndromic deafness associated with mitochondrial 12S rRNA mutation, *Hum. Mol. Genet.* 5 (1996) 963–972.
- [23] M.X. Guan, N. Fischel-Ghodsian, G. Attardi, Nuclear background determines biochemical phenotype in the deafness-associated mitochondrial 12S rRNA mutation, *Hum. Mol. Genet.* 10 (2001) 573–580.
- [24] M.X. Guan, N. Fischel-Ghodsian, G. Attardi, A biochemical basis for the inherited susceptibility to aminoglycoside ototoxicity, *Hum. Mol. Genet.* 9 (2000) 1787–1793.
- [25] M.J. Rieder, S.L. Taylor, V.O. Tobe, D.A. Nickerson, Automating the identification of DNA variations using quality-based fluorescence re-sequencing: analysis of the human mitochondrial genome, *Nucleic Acids Res.* 26 (1998) 967–973.
- [26] S. Anderson, A.T. Bankier, B.G. Barrell, M.H.L. deBruijn, A.R. Coulson, J. Drouin, I.C. Eperon, D.P. Nierlich, B.A. Rose, F. Sanger, P.H. Schreier, A.J.H. Smith, R. Staden, I. Young, Sequence and organization of the human mitochondrial genome, *Nature* 290 (1981) 457–465.
- [27] D. Moazed, H.F. Noller, Interaction of antibiotics with functional sites in 16S ribosomal RNA, *Nature* 327 (1987) 389–394.
- [28] P. Purohit, S. Stern, Interactions of a small RNA with antibiotic and RNA ligands of the 30S subunit, *Nature* 370 (1994) 659–662.
- [29] Q. Yan, X. Li, G. Faye, M.X. Guan, Mutations in *MTO2* related to tRNA modification impair mitochondrial gene expression and protein synthesis in the presence of a paromomycin resistance mutation in mitochondrial 15S rRNA, *J. Biol. Chem.* 280 (2005) 29151–29157.
- [30] K. Hamasaki, R.R. Rando, Specific binding of aminoglycosides to a human rRNA construct based on a DNA polymorphism, which causes aminoglycoside-induced deafness, *Biochemistry* 36 (1997) 12323–12328.